11 AUG – Dear Director,
so many things have been said and will be said on the "Revision of health spending" (the Spending Review) that there is really no need to add anything else.
The purpose of the following lines is only to make a contribution and try to clarify an aspect that I believe is "exquisitely technical" related to the Software or the Medical File of the family doctor on which too many inaccuracies prevail while neglecting the real problem.
For the sake of completeness, I quote the offending article 11-bis:
The doctor who treats a patient, for the first time, for a chronic pathology, or for a new episode of non-chronic pathology, for the treatment of which more equivalent medicines are available, is required to indicate in the prescription of the National Health Service only the name of the active ingredient contained in the drug. Any prescription of a specific medicine among the equivalent ones must be justified by the doctor with a brief written justification.
On many sources of information including on an agenda of August 4 of the Chamber of Deputies read:
…the aforementioned regulatory requirement, as complained by various acronyms representing doctors, will produce a substantial increase in costs for the regional and national administrations since the software houses of the computerized medical records will have to totally modify the management software in order to allow the doctor to prescribe the principle active, today not codified in the software as it is not foreseen by any nomenclator in use.
Lots of inaccuracies and confusion. For example, the medical file that I use like many general practitioners (it seems to me that there are over 16 thousand), MilleWin is already able to print the active ingredient, as well as I know the vast majority of SW used by family doctors.
The real "technical" problem linked to the prescription of the "Active Principle", which must be addressed as soon as possible among the SH with SOGEI is another. For more than a year, the project known as e-Prescription was launched or is being launched throughout the national territory, which provides for the electronic transmission of the prescription to the MEF. A fundamental requirement of the Project is that in the Therapeutic Prescriptions (Drugs) sent electronically there is "compulsory" (otherwise the prescription is rejected as invalid) the cod. MINSAN del Farmaco which is impossible if only the active ingredient is indicated.
In fact, to the question: "But how will pharmaceutical prescriptions of only the active ingredient that arrive without the MINSAN code be treated?"
Answer follows: “It is a new regulation of the Spending Review and we are discussing it with the Ministry of Health and with the State Accounting Office. At the moment we have no information."
Sapphi Giustini
